Clinical Trial Update: Study to Investigate the Efficacy, Safety and Tolerability of AZD1152 Alone and in Combination With Low Dose Cytosine Arabinoside (LDAC)in Acute Myeloid Leukaemia (AML) Patients [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial evaluating AZD1152 alone and with low-dose cytosine arabinoside in acute myeloid leukemia has completed with posted results in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• AZD1152 (barasertib)

Snippet

Sponsor: AstraZeneca | Conditions: Acute Myeloid Leukemia | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2014-03-31